Antipsychotic Long-acting Injections

Dr Peter Haddad is Consultant Psychiatrist at Greater Manchester West Mental Health NHS Foundation Trust, UK and Honorary Clinical Professor of Psychiatry at the University of Manchester, UK. He has a major clinical and research interest in pharmacological treatment of major mental illnesses (depression, bipolar disorder, schizophrenia) including adherence. He is also interested in improving the physical health of those with serious mental illness.

Professor Tim Lambert is Professor of Psychiatry at Concord Clinical School at The University of Sydney in Australia. He also holds an appointment as Head of Schizophrenia Treatment and Outcomes Research at the Brain & Mind Research Institute in Sydney. In addition, he fulfils clinical duties for Sydney Local Health Network as Director of the Centre of Excellence in Relapse Prevention in Psychosis (CERP), and at the Concord Centre for Cardiometabolic Health in Psychosis (ccCHiP). His
current interests focus on services research (pharmacoepidemiology, developing novel relapse prevention, treatment resistance, and cardiometabolic services for the seriously mentally ill); the clinical pharmacology of LAI antipsychotics (first and second generation) and of the second-generation antipsychotics,
particularly risk-benefit aspects and the applied clinical pharmacology of antipsychotic switching; physical comorbidities of psychotic disorders, especially cardiometabolic syndromes; and incomplete recovery.

Professor John Lauriello is Professor and Chair of the Department of Psychiatry, University of Missouri, School of Medicine, Columbia, Missouri, USA. He specializes in the diagnosis and treatment of psychotic disorders, most notably schizophrenia.